The treatment resistant depression market involves pharmaceutical drugs that are used for treating depression which does not respond to several antidepressant medications. Key pharmaceutical drugs used in the treatment resistant depression market include antidepressants, atypical antipsychotics, Neurostimulation therapies and cannabidiol based pharmaceutical drugs. Some of the key advantages of cannabidiol based pharmaceutical drugs are that they have minimal side effects and act on multiple receptor targets in the brain which help in reducing depression symptoms. With increasing number of people not responding to conventional antidepressants, the need for alternative treatment options like cannabidiol based drugs is rising significantly.
The Global Treatment Resistant Depression Market Demand is estimated to be valued at US$ 1405.58 Mn in 2024 and is expected to exhibit a CAGR of 22.% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the treatment resistant depression market are HempFlax, Cavac Biomateriaux, BaFa, Hemp Planet, Dunagro, American Hemp, Hempline, Hemp Inc, Ecofibre, GenCanna, Hemp Oil Canada, Hemp Poland, Plains Industrial Hemp Processing, Colorado Hemp Works, MH Medical Hemp, Hempco, Hempfield Farms, Hemp Tech, Tilray, Canopy Growth.
Some of the key opportunities in the treatment resistant depression market include increasing adoption of cannabidiol as an alternative treatment, growing clinical trials to prove efficacy of cannabidiol based drugs and approval of new cannabidiol pharmaceutical products.
The treatment resistant depression market is expanding globally due to increasing focus of pharmaceutical companies on new drug development, growing patient pool worldwide especially in Asia Pacific and Latin America and presence of supportive government regulations in countries like Canada and some European nations.
Market Drivers
One of the major market driver for treatment resistant depression market is growing usage of cannabidiol based pharmaceutical drugs. Clinical studies have shown cannabidiol to be effective in managing depression symptoms with minimal side effects compared to other antidepressants. This is driving its increased adoption among doctors and patients for treatment resistant depression cases.
PEST Analysis
Political: The Treatment Resistant Depression market is regulated by various agencies and policies set by countries for the marketing and promotion of drugs and therapies. Regulations around the use of cannabis and new formulations can impact the market.
Economic: The economic conditions and healthcare spending of countries impacts the expenditure on treatment and adoption of new therapies. Rising income levels globally is driving more spend on mental healthcare.
Social: Growing awareness and reduced stigma around mental illnesses is encouraging more people to seek treatment. Social support systems play a key role in managing treatment resistant depression.
Technological: Advancements in drug delivery systems, novel formulations and development of digital therapeutics are expanding the treatment options available. Personalized and precision medicines can help address specific patient needs.
The market in terms of value is concentrated in regions like North America and Europe owing to higher healthcare spends and developed healthcare systems. Countries like the US, Canada, Germany, UK and France account for a major share of the global market currently.
The Treatment Resistant Depression market is witnessing the fastest growth in the Asia Pacific region due to improving access to therapies, rising incidence of depression and growing expenditure capability in countries like China, India and South Korea. Increased penetration of health insurance is also supporting market growth in the Asia Pacific region.
For more details on the report, Read- https://www.trendingwebwire.com/treatment-resistant-depression-market-size-share-analysis/
